Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $539000.0.

  • Lineage Cell Therapeutics' Other Non-Current Assets fell 1105.61% to $539000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $539000.0, marking a year-over-year decrease of 1105.61%. This contributed to the annual value of $614000.0 for FY2024, which is 641.25% up from last year.
  • Lineage Cell Therapeutics' Other Non-Current Assets amounted to $539000.0 in Q3 2025, which was down 1105.61% from $511000.0 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Other Non-Current Assets registered a high of $639000.0 during Q1 2022, and its lowest value of $504000.0 during Q1 2025.
  • Moreover, its 5-year median value for Other Non-Current Assets was $598000.0 (2022), whereas its average is $591052.6.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Other Non-Current Assets surged by 978.26% in 2024 and then plummeted by 1543.62% in 2025.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Other Non-Current Assets stood at $630000.0 in 2021, then decreased by 0.48% to $627000.0 in 2022, then fell by 7.97% to $577000.0 in 2023, then grew by 6.41% to $614000.0 in 2024, then dropped by 12.21% to $539000.0 in 2025.
  • Its Other Non-Current Assets was $539000.0 in Q3 2025, compared to $511000.0 in Q2 2025 and $504000.0 in Q1 2025.